Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026
Longeveron (NASDAQ: LGVN) will report 2025 full-year financial results and provide a business update on Tuesday, March 17, 2026 after U.S. markets close.
Rhea-AI Summary
Longeveron (NASDAQ: LGVN) will report 2025 full-year financial results and provide a business update on Tuesday, March 17, 2026 after U.S. markets close. The company will host a conference call and webcast the same day at 4:30 p.m. ET. An archived replay will be available on the company website under Events & Presentations.
Positive
- None.
Negative
- None.
Details
News Market Reaction – LGVN
On Mar 12, the day this news came out, LGVN closed 0.43% below the previous close.
Data tracked by StockTitan Argus for the Mar 12 session.
Key Figures
- Earnings report date
- March 17, 2026
- Scheduled 2025 full-year financial results release
- Earnings release time
- After market close
- Timing of 2025 full-year results announcement
- Conference call time
- 4:30 p.m. ET
- Scheduled investor conference call and webcast
- Conference call number
- 1.877.407.0789
- Dial-in number for the results call
- Conference ID
- 13758462
- Access code for the earnings conference call
Historical Context
-
Announced private placement up to $30M to fund operations into 4Q2026.
-
Reported Phase 2b data showing improved 6MWT in age-related frailty.
-
Appointed Stephen H. Willard as CEO with focus on Phase 2b HLHS data.
-
Highlighted PRV program reauthorization and progress of 40‑patient HLHS trial.
-
Announced Japan patent grant extending MSC potency assay IP to 2041.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MIAMI, March 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report 2025 full year financial results and provide a business update on Tuesday, March 17, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET.
Conference Call and Webcast Details:
| Conference Call Number: | 1.877.407.0789 |
| Conference ID: | 13758462 |
| Call meTM Feature: | Click Here |
| Webcast: | Click Here |
An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (LOMECEL-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), Pediatric Dilated Cardiomyopathy (PDCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.